NIH-funded report flags high-volume certifiers, potential diversion in Arkansas medical-marijuana market

Dr. Joe Thompson, CEO of the Arkansas Center for Health Improvement, presented the first NIH-funded population-based analysis of Arkansas s medical marijuana program produced under the state's transparency initiative. He said the study used medical licensure data, cardholder qualification data, dispensary transactions and the state's all-payer claims database (which covers roughly 80% of paid claims) to profile who participates, what they buy and whether certifications appear integrated with usual medical care.

Key program features and findings presented: - Program structure: authorized by constitutional amendment; first dispensary opened May 2019; purchasing limit is expressed as an "equivalent of 2.5 ounces of flower every two weeks" under the constitution. Thompson explained that because limits are tied to flower weight rather than THC content, users can obtain very large THC-equivalents ("you can buy 7,000 gummies every 2 weeks," he said), creating potential diversion pathways. - Participation and transactions: slides showed tens of thousands of qualified individuals (Thompson cited approximately 76,000 qualified individuals in one analysis and different contemporaneous counts in other slides), roughly 100,000 cardholder population referenced on transaction slides, and monthly dispensary transactions approaching 300,000–400,000. - Consumption and dosing: the team estimated an overall average of about 160 mg of THC per day purchased per user, with higher averages for flower purchasers (206 mg/day) and lower for edibles (35 mg/day) and vapes (20 mg/day); maximum per-user amounts in the data reached several hundred milligrams to 900 mg/day in some product categories, which Thompson said likely indicates diversion rather than personal consumption. - Physician patterns: of ~6,871 actively licensed physicians, ~12% certified at least one patient in 2021; the majority certified fewer than 10 patients, while seven physicians certified over 1,000 each and collectively represented over one-third of cards issued in that year. Thompson said lower-volume certifiers were more likely to have concordant diagnostic claims and clinical continuity with their certified patients, while high-volume certifiers often had low rates of concordant diagnostic claims. - Early clinical outcome: in a matched analysis of 2,500 patients with diagnosed PTSD in claims data, researchers observed no change in antidepressant or anxiolytic prescriptions but reported fewer hospitalizations among medical-marijuana users versus matched nonusers (approximately four fewer hospitalizations per 100 individuals over the year after certification). Thompson emphasized that findings are preliminary and peer-reviewed for methods.

Policy implications and committee requests: Thompson suggested policy options including strengthening documentation of the patient-physician relationship in certifications, integrating certifications into the PDMP so clinicians can be aware of medical-marijuana use among their patients, and shifting purchase limits to total THC amounts rather than flower weight. Committee members pressed for follow-up cross-tabulations linking purchases per patient to certifying physician, age breakdowns, data on children who are cardholders via caregivers, and dollar estimates of hospitalization savings tied to reduced admissions. Thompson offered to return with more targeted analyses in response to the committee's questions.

Thompson closed by noting continued planned work on opioid substitution in chronic-pain patients, tracking cannabis-use diagnoses, and population-level outcomes (hospitalizations, motor-vehicle accidents, deaths).